1 / 12

Correlation of Serum Thymidine Kinase in the Prognosis/Treatment of Cancer

Correlation of Serum Thymidine Kinase in the Prognosis/Treatment of Cancer By: Danielle Cervantes. Thymidine Kinase A transferase enzyme that catalyzes phosphorylation of drugs into a form that will be active against viruses. Dot Blot Assay

david-wilcox
Download Presentation

Correlation of Serum Thymidine Kinase in the Prognosis/Treatment of Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Correlation of Serum Thymidine Kinase in the Prognosis/Treatment of Cancer By: Danielle Cervantes

  2. Thymidine Kinase A transferase enzyme that catalyzes phosphorylation of drugs into a form that will be active against viruses. Dot Blot Assay Technique similar to Western Blotting that involves separating proteins by spotting through a circular template directly onto the cell membrane. Receiver Operating Characteristic An analytical test that determines the specificity and selectivity of a medical test. Specificity Odds that a test will be negative in the absence of a disease Selectivity Odds that a test will be positive in the presence of a disease

  3. Non-Hodgkin's Lymphoma • Is a class of cancers that affect the white blood cells • Can be aggressive or indolent • Estimated New Cases & Deaths in US in 2010 • Cases: 65,540 • Deaths: 21,210 cancer.osu.edu

  4. STK1 as a Prognostic Factor Used in prognosis after chemotherapy treatment Levels were determined by chemiluminescent dot-blot assay Before chemo, and 1 & 28 days after STK1 levels were analyzed two ways 1) Western blot using an anti-TK1 IgY antibody 2) Receiver Operating Characteristic (ROC) analysis

  5. STK1 as a Prognostic Factor Results Mean STK1 levels were much higher in patients with non-Hodgkin's lymphoma than in healthy people Levels decreased until at day 28 the level corresponded with that of a healthy person The mean of the STK1 levels was significantly correlated with the clinical response and 5-year survival rate

  6. Electrochemiluminescence (ECL) Assay • Designed to detect biological threats • antigen complexes with 2 antibodies • 1) attached to a magnetic particle • 2) modified with a reporter molecule • Electrode attracts magnetic particle and the detector emits light. • Measured light is correlated with presence of antigen labautopedia.org

  7. Complete Response (Complete Remission) Disappearance of all signs of cancer after treatment Partial Response (Partial Remission) Decrease in size of tumor or extent of cancer after treatment Stable Disease Cancer that is not increasing or decreasing in extent/severity Progressive Disease Cancer that's growing/spreading/getting worse Metastasis Process of cancer spreading from first location to another. Cancer resulting from the spread of the primary tumor

  8. STK1 in Cancer Treatment Experiment examined significance of STK1 in clinical settings Monitored 1,247 patients Concentration of STK1 was determined by ECL assay Value was correlated to clinical stage & reaction Monitored outcome of surgery/multi-drug chemo Looked at 5 different carcinomas Lung, esophagus, gastric, head & neck, & thyroid

  9. Results STK1 values correlated with clinical stage in 4 of 5 carcinomas Levels declined in all tumor groups after treatment In CR or PR patients levels decreased or were <2pM In SD or PD patients levels increased or were >2pM Some showed metastasis Overall STK1 correlates to clinical stages and reactions. It also monitors effectiveness of therapies in controlled/routine clinical trials

  10. Overall Results STK1 is a good indicator as to the presence of non-Hodgkin's lymphoma in patients STK1 is a good indicator of the effectiveness of treatment of different carcinomas It is not a good indicator of the effectiveness of treatment in head & neck carcinomas

  11. Significance of Results The results of these two studies show that levels of STK1 can be used as a prognostic and monitoring factor in cancer. This means that more invasive/expensive procedures can be omitted in treatment.

  12. References "Serum Thymidine Kinase 1 Correlates to Clinical Stages and Clinical Reactions and Monitors the Outcome of Therapy of 1,247 Cancer Patients in Routine Clinical Settings." http://www.cancer.gov http://www.antibodybeyond.com/applications/dotblot.htm "Electrochemiluminescence (ECL) Assay." <www.jpeocbd.osd.mil/packs/DocHandler.ashx?DocID=8597>. http://www.cancer.gov/cancertopics/types/non-hodgkin "Serum Thymidine Kinase 1 Concentration as a Prognostic Factor of Chemotherapy-treated Non-Hodgkin's Lymphoma Patients." http://www.medcalc.be/manual/roc.php

More Related